Sign In
Buy TXMD
$1.97
-0.0700 (-3.43%)
At Close: Jun 03, 2026
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
06:50am, Tuesday, 03'rd Jan 2023
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced tha
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
06:00pm, Sunday, 04'th Dec 2022
BOCA RATON, Fla.--( BUSINESS WIRE )--TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women's healthcare company, today announced tha
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
09:03pm, Monday, 14'th Nov 2022
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD Announces Third Quarter 2022 Financial Results
04:05pm, Monday, 14'th Nov 2022
BOCA RATON, Fla.--( BUSINESS WIRE )--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today reported financial results for the
TherapeuticsMD Announces Additional $7 Million Private Placement
06:50am, Monday, 31'st Oct 2022
BOCA RATON, Fla.
TherapeuticsMD Announces $7 Million Private Placement
06:50am, Monday, 03'rd Oct 2022
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TherapeuticsMD” or the “Company”) an innovative, leading women's healthcare company, announced today that it received
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
09:47am, Monday, 15'th Aug 2022
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of 29.28% and 23.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
TherapeuticsMD, Inc. (TXMD) CEO Hugh O'Dowd on Q2 2022 Results - Earnings Call Transcript
09:46am, Monday, 15'th Aug 2022
TherapeuticsMD, Inc. (NASDAQ:TXMD ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 PM ET Company Participants Lisa Wilson - IR Hugh O'Dowd - CEO Michael Donegan - Interim CFO Mark Glickman - Ch
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
06:50am, Monday, 08'th Aug 2022
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women's healthcare company, today announced that it will report its sec
Why TherapeuticsMD Shares Are Sinking Today?
09:59am, Wednesday, 13'th Jul 2022
Women's healthcare company TherapeuticsMD Inc (NASDAQ: TXMD) shares are falling as EW Healthcare Partners did not acquire the required majority of shares of TXMD through the previously announced
TherapeuticsMD's stock falls 41% after tender offer expires
08:25am, Wednesday, 13'th Jul 2022
Shares of TherapeuticsMD Inc. TXMD, +8.67% tumbled 41.6% in premarket trading on Wednesday after the women's health company told investors that EW Healthcare Partners' planned acquisition of Therapeut
5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More
12:01pm, Tuesday, 21'st Jun 2022
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback
02:43pm, Thursday, 16'th Jun 2022
TherapeuticsMD's $177 million buyout deal with EW Healthcare largely undervalues the biotech. TherapeuticsMD is close to stimulating the commercialization of Annovera which may increase its value as a
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
Why EW Healthcare Partners Is Buying TherapeuticsMD (TXMD) In A $177 Million Deal
02:47pm, Tuesday, 31'st May 2022
TherapeuticsMD, Inc. (NASDAQ: TXMD) announced it entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Partners as part of a $177 million deal. These are the detai
